…
MyndTec Inc., a medical technology company, researches, develops, and distributes therapies for individuals with paralysis due to stroke or spinal cord injury in Canada, the United States, and Malaysia. The company offers MyndLink, an AI-powered system designed to enhance spinal cord stimulation (SCS) treatment outcomes by providing real-time, data-driven recommendations; MyndMove, a non-invasive functional electrical stimulation therapy designed to improve voluntary arm and hand function in patients with upper-limb paralysis, such as those suffering from stroke or spinal cord injury; and cell regeneration technology for the treatment of neurological diseases. It also provides MyndSearch or MyndStep devices to clinics and research institutions, as well as treatment supplies. The company was formerly known as Simple Systems Inc. and changed its name to MyndTec Inc. in April 2013. MyndTec Inc. was incorporated in 2008 and is headquartered in Mississauga, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for MyndTec Inc. (MYTC.CN) are limited, so the company's core business and financial position are not clearly described in widely available sources. Any long-term growth would likely depend on successful product development, market entry, regulatory approvals or strategic partnerships, which could support revenue if execution succeeds.
Key risks include low liquidity, limited operating history or revenues, execution and financing risk, competitive pressure and regulatory uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -1.25M | -1.72M | -2.13M | -3.05M | -1.49M |
| Net income | -1.25M | -1.72M | -2.13M | -3.05M | -1.49M |
| Selling general administrative | 0.80M | 1.00M | 1.31M | 1.34M | 1.50M |
| Gross profit | 0.00M | 0.05M | 0.07M | 0.35M | 0.07M |
| Reconciled depreciation | 0.10M | 0.12M | 0.13M | 0.11M | 0.12M |
| Operating income | -1.23M | -1.59M | -2.03M | -2.72M | -1.71M |
| Interest expense | 0.02M | 0.02M | 0.12M | 0.32M | 0.23M |
| Interest income | 0.00M | - | 0.01M | 0.00M | - |
| Net interest income | -0.02M | -0.02M | -0.11M | -0.32M | -0.23M |
| Total revenue | 0.11M | 0.14M | 0.26M | 0.61M | 0.16M |
| Total operating expenses | 1.34M | 1.73M | 2.29M | 3.32M | 1.87M |
| Cost of revenue | 0.11M | 0.08M | 0.19M | 0.25M | 0.10M |
| Total other income expense net | 0.00M | -0.11M | 0.01M | -0.01M | 0.44M |
| Net income from continuing ops | -1.25M | -1.72M | -2.13M | -3.05M | -1.49M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 0.31M | 0.55M | 0.64M | 3.82M | 1.65M |
| Total liab | 1.55M | 1.47M | 1.57M | 7.37M | 3.48M |
| Total stockholder equity | -1.24M | -0.92M | -0.93M | -3.54M | -1.83M |
| Other current liab | -0.00M | - | 0.49M | 2.71M | 0.19M |
| Capital stock | 15.72M | 14.97M | 13.85M | 11.01M | 10.09M |
| Retained earnings | -20.93M | -19.68M | -17.96M | -15.82M | -12.77M |
| Cash | 0.12M | 0.19M | 0.07M | 0.38M | 0.67M |
| Total current liabilities | 1.51M | 1.44M | 1.27M | 5.75M | 1.05M |
| Net debt | 0.35M | 0.26M | 0.17M | 1.65M | 1.04M |
| Short long term debt | 0.44M | 0.45M | 0.46M | 1.43M | - |
| Total current assets | 0.27M | 0.44M | 0.40M | 3.48M | 1.34M |
| Net receivables | 0.00M | 0.01M | 0.03M | 0.28M | 0.17M |
| Long term debt | 0.02M | - | 0.24M | 0.59M | 1.71M |
| Inventory | 0.12M | 0.18M | 0.26M | 0.30M | 0.32M |
| Accounts payable | 0.33M | 0.24M | 0.20M | 1.55M | 0.64M |
| Non current assets total | 0.04M | 0.12M | 0.24M | 0.34M | 0.31M |
| Capital lease obligations | 0.00M | 0.01M | 0.01M | 0.05M | 0.00M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -0.02M | 0.00M | -0.04M | -0.06M | -0.02M |
| Net borrowings | -0.01M | -0.03M | -0.15M | -0.21M | - |
| Total cash from financing activities | 0.87M | 1.10M | 2.08M | 1.21M | 1.67M |
| Net income | -1.25M | -1.72M | -2.13M | -3.05M | -1.49M |
| Change in cash | -0.07M | 0.12M | -0.31M | -0.29M | 0.25M |
| Begin period cash flow | 0.19M | 0.07M | 0.38M | 0.67M | 0.42M |
| End period cash flow | 0.12M | 0.19M | 0.07M | 0.38M | 0.67M |
| Total cash from operating activities | -0.92M | -0.98M | -2.34M | -1.44M | -1.40M |
| Issuance of capital stock | 0.88M | 1.15M | 2.26M | 0.83M | 0.10M |
| Depreciation | 0.10M | 0.12M | 0.11M | 0.11M | 0.12M |
| Change to inventory | 0.07M | 0.07M | 0.05M | 0.02M | -0.02M |
| Change to account receivables | - | - | - | -0.14M | 0.16M |
| Capital expenditures | 0.02M | 0.00M | 0.04M | 0.06M | 0.02M |
| Change in working capital | 0.18M | 0.32M | -0.69M | 0.96M | 0.11M |
| Stock based compensation | 0.05M | 0.20M | 0.24M | 0.13M | 0.10M |
| Other non cash items | 0.00M | 0.11M | 0.10M | 0.42M | -0.22M |
| Free cash flow | -0.94M | -0.98M | -2.39M | -1.50M | -1.41M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MYTC MyndTec Inc. |
- -% |
0.01 | - | - | 0.99 | 61.93 | 3.76 | -8.57 |
| BLO Cannabix Technologies Inc |
-0.04 9.09% |
0.35 | - | - | 556.83 | 57.80 | 564.68 | -11.28 |
| ASTI Aquarius Surgical Technologies Inc |
- -% |
0.01 | - | - | 5.52 | 31.44 | 96.08 | 56.94 |
MyndTec Inc., a medical technology company, researches, develops, and distributes therapies for individuals with paralysis due to stroke or spinal cord injury in Canada, the United States, and Malaysia. The company offers MyndLink, an AI-powered system designed to enhance spinal cord stimulation (SCS) treatment outcomes by providing real-time, data-driven recommendations; MyndMove, a non-invasive functional electrical stimulation therapy designed to improve voluntary arm and hand function in patients with upper-limb paralysis, such as those suffering from stroke or spinal cord injury; and cell regeneration technology for the treatment of neurological diseases. It also provides MyndSearch or MyndStep devices to clinics and research institutions, as well as treatment supplies. The company was formerly known as Simple Systems Inc. and changed its name to MyndTec Inc. in April 2013. MyndTec Inc. was incorporated in 2008 and is headquartered in Mississauga, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Craig Leon MBA | CEO & Director | 1968 |
| Mr. Jing Peng | Chief Financial Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.